Lates News
AstraZeneca: Baxdrosdat (Baxdrostat) met the primary endpoint and all secondary endpoints in the BaxHTN phase III trial. The 2 mg dose of Baxdrosdat reduced systolic blood pressure by 15.7 mmHg from baseline (9.8 mmHg after placebo correction). Overall, Baxdrosdat was well-tolerated with no unexpected safety issues.
Latest